No Data
China Galaxy Securities: A review of the fifth set of standards on the Star has significantly boosted investment in the pharmaceutical industry.
Future reforms in diversified payment for commercial insurance are expected to bring marginal improvements from a policy perspective, and there are good long-term investment opportunities in pharmaceutical innovation and related industries.
Express News | Mabwell's Nectin-4 Targeted ADC 9MW2821 Combination Therapy Demonstrates 87.5% Orr and Granted Cde Breakthrough Therapy Designation
Mabwell (Shanghai) Bioscience Gets Breakthrough Therapy Designation for Anti-Cancer Injectable
New stock news | Maiwei Bio has submitted its application to the Hong Kong Stock Exchange, with CITIC and Haitong as co-sponsors.
Maiwei Biotech is a pharmaceutical company primarily focused on the independent development of drugs for tumors and age-related diseases, currently in the commercialization stage.
Maiwei Bio (688062.SH): has submitted a Listed in Hong Kong issuance application and published application materials.
Maiwei Biotech (688062.SH) announced that the company has submitted to the Hong Kong Stock Exchange on January 6, 2025...
Mabwell: HK Listing to Help Capital Needs of Business, Promote Sustainable Development
No Data
